OFIRMEV approved for Prior Approval Supplement

OFIREMEV will now be available in an intravenous bag. | File photo

Mallinckrodt Pharmaceuticals' OFIRMEV injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration.

OFIREMEV will now be available in an intravenous bag, giving an additional method of delivery to health care providers.

The  Prior Approval Supplement will include the new container closure and the manufacturer of the product being added. Fresenius Kabi will take on the job of manufacturing the polypropylene bags.

Mallinckrodt expects the product to hit the market in the second quarter of 2017.

Want to get notified whenever we write about Mallinckrodt Pharmaceuticals ?
Next time we write about Mallinckrodt Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Mallinckrodt Pharmaceuticals 675 McDonnell Blvd. St. Louis, MO 63042